ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failureSimon Oczkowski, Raffaele Scala, Leo Heunks et al.|European Respiratory Journal|2021Cited by 385
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Sanne de Bruin et al.|The Lancet Rheumatology|2020Cited by 199
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143
Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patientsRutger Koning, Esther J. Nossent, Paul Bastard et al.|Intensive Care Medicine|2021Cited by 132
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical UseZoltán Papp, Bojan Vrtovec, Piergiuseppe Agostoni et al.|Journal of Cardiovascular Pharmacology|2020Cited by 111